Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (STRIDERCan)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02442492
Recruitment Status : Terminated (Trial terminated following Dutch DSMB recommendation for their Study)
First Posted : May 13, 2015
Last Update Posted : May 7, 2019
Sponsor:
Information provided by (Responsible Party):
Kenneth Lim, University of British Columbia

Brief Summary:
Early-onset placental intrauterine growth restriction (EO IUGR) is associated with a high risk of perinatal morbidity and mortality. In association with reduced circulating placental growth factor (PlGF) EO IUGR results from abnormal placentation with inadequate remodelling of the maternal uteroplacental arteries. There is no known treatment for placental IUGR. Management involves intensive fetal surveillance with delivery with evidence of serious fetal compromise. However, remote from term, delivery is associated with significant perinatal mortality and morbidity. Sildenafil vasodilates the uteroplacental vessels of IUGR-affected pregnancies and may represent a novel therapy.

Condition or disease Intervention/treatment Phase
Intrauterine Growth Restriction (IUGR) Fetal Growth Restriction (FGR) Drug: Sildenafil Drug: Placebo Phase 2 Phase 3

Detailed Description:

STRIDER Canada is one of a consortium of STRIDER randomised controlled trials (RCTs) each of which is designed to determine whether or not maternal treatment with oral sildenafil citrate improves perinatal outcomes in pregnancies complicated by EO IUGR without increasing risks to the mother.

STRIDER Canada is designed as investigator-initiated double-blind, randomised placebo-controlled trial of 90 women with a diagnosis of early-onset intrauterine growth restriction with an intention-to-treat analysis. 90 Women with affected pregnancies will be recruited and randomised to receive either sildenafil or placebo.

Women reviewed in the participating fetal medicine with a diagnosis of a pregnancy affected by early-onset IUGR between 18+0 and 27+6 weeks of gestation and serum PlGF levels less than 5th percentile for gestational age will be considered for randomisation. In Canadian STRIDER, the treatment with either sildenafil or placebo (25 mg 3 times per day) will be applied from the time of randomisation until delivery, or up to 31+6 weeks of gestation whichever comes first.

All patients randomly assigned to one of the treatments will be analysed together, regardless of whether or not they completed or received that treatment, on an intention to treat basis.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada)
Actual Study Start Date : January 2017
Actual Primary Completion Date : July 2018
Actual Study Completion Date : April 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Sildenafil
Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Drug: Sildenafil
Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.

Placebo Comparator: Placebo
Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Drug: Placebo
Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.




Primary Outcome Measures :
  1. compare the gestational age at delivery (d) between sildenafil- and placebo-treated groups [ Time Frame: 6 weeks after postpartum ]

Secondary Outcome Measures :
  1. live birth [ Time Frame: at delivery if alive ]
  2. survival to hospital discharge [ Time Frame: measured at the final hospital discharge (average upto 6 weeks postpartum) ]
  3. intact survival (defined as survival to estimated due date (EDD) without evidence of severe central nervous system [CNS] injury [by ultrasound and/or magnetic resonance imaging (MRI)]) [ Time Frame: measured at estimated due date (EDD) ]
  4. composite non-CNS (Central Nervous System) severe morbidity (one/more of bronchopulmonary dysplasia requiring supplemental oxygen on hospital discharge, ≥grade 3 retinopathy of prematurity, or necrotising enterocolitis) [ Time Frame: up to 6 weeks after postpartum or final discharge which ever is sooner ]

Other Outcome Measures:
  1. Maternal - symptomatic hypotension [ Time Frame: up to 6 weeks after postpartum or final discharge which ever is sooner ]
  2. Maternal - pre-eclampsia [ Time Frame: from randomisation to delivery (expected to be assessed weekly) ]
  3. Maternal - mode of delivery [ Time Frame: At delivery ]
  4. Maternal - haemorrhage requiring transfusion [ Time Frame: At delivery ]
  5. Maternal - maternal plasma PlGF. [ Time Frame: from randomisation to delivery (expected to be assessed weekly) ]
  6. Maternal - uterine artery Doppler indices [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
  7. Perinatal - fetal growth velocity [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
  8. Perinatal - fetal Doppler [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
  9. Perinatal - amniotic fluid [ Time Frame: At randomisation, if done ]
  10. Perinatal - fetal heart indices [ Time Frame: rom randomisation to delivery (expected to be done weekly) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gestational age from 18+0 - 27+6 weeks

AND

  • EO IUGR, defined as

    1. ultrasound (U/S) measurement of the fetal abdominal circumference (AC) <10th percentile for gestational age and/or documented reduced fetal growth velocity complicating either a prior EO IUGR with adverse perinatal outcome or abnormal uterine artery waveform in the index pregnancy;

      OR

    2. U/S estimate of fetal weight (EFW) <700g

AND

  • Serum PlGF < 5th percentile for gestational age

Exclusion Criteria:

  • known fetal aneuploidy
  • known fetal anomaly/syndrome/congenital infection confirmed at the time of enrolment
  • decision made to terminate pregnancy
  • current cocaine or vasoconstrictor use (e.g. crystal meth) (risk of acute cardiac events)
  • contraindication to sildenafil therapy, e.g. known significant maternal cardiac disease, left ventricular outflow tract obstruction, concomitant treatment with nitrates or previous allergy to sildenafil
  • known HIV positive status (due drug-drug interaction between sildenafil and antiretrovirals)
  • receiving peripheral alpha-blockers (e.g. prazosin)
  • prior participation in a STRIDER trials
  • pre-eclampsia or gestational hypertension diagnosed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442492


Locations
Layout table for location information
Canada, Alberta
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5H 3V9
Canada, British Columbia
BC Women's Hospital/University of British Columbia
Vancouver, British Columbia, Canada, V7H3N1
Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 5W9
Canada, Quebec
CHU Sainte-Justine
Montréal, Quebec, Canada, H3T 1C5
CHU de Quebec - Universite Laval
Quebec City, Quebec, Canada, G2N 0B2
Sponsors and Collaborators
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Peter von Dadelszen, BMedSc, MBChB, DipObst, DPhil, University of British Columbia
Principal Investigator: Kenneth Lim, MD FRCSC University of British Columbia

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kenneth Lim, Study Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier: NCT02442492     History of Changes
Other Study ID Numbers: H15-00899
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: May 2019

Keywords provided by Kenneth Lim, University of British Columbia:
sildenafil
IUGR
FGR
STRIDER

Additional relevant MeSH terms:
Layout table for MeSH terms
Fetal Growth Retardation
Fetal Diseases
Pregnancy Complications
Growth Disorders
Pathologic Processes
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents